Results Two hundred of 245 (81.6%) included women completed the baseline and three-month questionnaires. The incidence of lymphedema was 7.2% versus 31.5% in women who underwent SLN mapping alone and completion PL, respectively ($p < 0.001$). Lymphedema scores in the leg, genital, and groin were affected in both groups, but significantly more after PL. The differences between groups remained significant in a multivariate analysis adjusting for, e.g., adjuvant therapy and age. PL significantly affected the severity of lymphedema regarding physical performance ($p = 0.001$), appearance ($p = 0.008$), besides heaviness, weakness, and pain in the legs ($p < 0.001$). Lymphedema was negatively associated with impaired body image, physical, role, and social functioning and a higher level of fatigue.

Conclusions SLN mapping combined with PL is associated with a significantly higher incidence and more severe lymphedema three months postoperatively than SLN mapping alone. Lymphedema was associated with lower QoL in several domains.

EPV050/#255 OVERUSE OF CERVICAL CANCER SCREENING TESTS AMONG AVERAGE-RISK MEDICAID BENEFICIARIES

¹J Dillon, ^{2,3,4}J Wright, ²L Chen, ³M Accordini, ²A Melamed, ³D Hershman. ¹Duke University School of Medicine, School of Medicine, Durham, USA; ²Columbia University College of Physicians and Surgeons, Gynecologic Oncology, New York City, USA; ³Herbert Irving Comprehensive Cancer Center, Oncology, New York City, USA; ⁴New York Presbyterian Hospital, Oncology, New York City, USA

10.1136/ijgc-2021-IGCS.118

Objectives In 2012, the American Cancer Society updated cervical cancer screening guidelines to recommend cytologic screening every 3 years or HPV testing with cytology (co-testing) every 5 years in women age 30–65. We aim to examine the use of cervical cancer screening among average-risk Medicaid beneficiaries.

Methods The MarketScan database was used to identify average-risk women age 30–64 with Medicaid coverage who underwent index cervical cancer screening in 2013–2016. Subsequent screening rates within 3 years of the index test were examined. Demographic factors associated with early re-screening and rates of annual gynecologic examinations were also

Abstract EPV050/#255 Figure 1 Cervical cancer screening by month

examined. Patients with cervical dysplasia, HPV, or unsatisfactory results were excluded.

Results Overall, 265,083 patients were included. 43.1% (N=114,312) had index co-testing, 55.2% (N=146,309) had cytology, and 1.7% (N=4,462) had primary HPV testing. The cumulative incidence of early, repeat cervical cancer screening was 3.9% at 12mo, 22.7% at 24mo, and 33.3% at 36mo. During the period from 12–24 months after follow-up, 20.9% of women underwent repeat screening, while 19.4% underwent screening 24–36 months after the index test. Early re-testing was more common in younger patients and non-White patients ($p < 0.001$). Of patients who did not undergo repeat cervical cancer screening, a yearly gynecologic examination was performed in only 16,627 (10.7%) during year 2 and in 11,116 (8.8%) patients during year 3.

Conclusions Among average-risk Medicaid beneficiaries, cervical cancer screening is frequently overutilized. Women who do not undergo cervical cancer screening are unlikely to receive routine gynecologic care.

EPV051/#264 SMALL CELL NEUROENDOCRINE CARCINOMA OF THE CERVIX IN A YOUNG PATIENT WITH UTERINE PROCIDENTIA: A CASE REPORT

M Garcia*, I Tagayuna. Tondo Medical Center, Obstetrics and Gynecology, Manila, Philippines

10.1136/ijgc-2021-IGCS.119

Objectives Small cell neuroendocrine carcinoma of the cervix (SCNC) is an aggressive and rare histologic subtype, accounting for less than 2% of all cervical tumors. Moreover, cervical cancer complicated with uterine prolapse is even rarer with an estimated incidence of 0.14–1.0%.

Methods A 32-year-old multipara presented with a 13-month history of intermittent vaginal spotting and postcoital bleeding, associated with gradually increasing introital mass. Pelvic examination revealed procidentia uteri. A foul-smelling fungating, necrotic mass at the anterior lip of the cervix measuring 9 x 9 x 4.5 cm was also noted. Biopsy of the mass and

Abstract EPV051/#264 Figure 1

Abstract EPV051/#264 Figure 2

immunohistochemistry were consistent with SCNC. Imaging studies were done to determine the extent of the tumor. A diagnosis of small cell neuroendocrine carcinoma of the cervix, stage IIIC1r with pelvic organ prolapse, stage IVC was made. Uterine procidentia was reduced using a gellhorn pessary. The patient received external beam radiation therapy followed by brachytherapy, and chemotherapy with Cisplatin and Etoposide.

Results There was marked reduction of the cervical mass, and complete resolution of the pelvic organ prolapse, as well.

Conclusions This is the first report of small cell neuroendocrine carcinoma of the cervix complicated with uterine procidentia, locally and internationally. It required a multidisciplinary approach involving a urogynecologist, a gynecologic oncologist, and a radiation oncologist. Standard treatment guidelines for this rare tumor and case are yet to be established.

EPV052/#273

A NOVEL IMAGE-GUIDED POINT-OF-CARE ETHYL CELLULOSE ETHANOL ABLATION STRATEGY FOR RECURRENT LOCALIZED CERVICAL CANCER

^{1,2,3}J Agudogo*, ²C Nief, ²A Gonzales, ⁴J Mueller, ²B Crouch, ⁵R Previs, ²N Ramanujam. ¹Duke University, School of Medicine, Durham, USA; ²Duke University, Biomedical Engineering, Durham, USA; ³Duke University, Center For Global Women's Health Technologies, Durham, USA; ⁴University of Maryland, School of Engineering, College Park, USA; ⁵Duke University School of Medicine, Obstetrics and Gynecology, Durham, USA

10.1136/ijgc-2021-IGCS.120

Objectives Local ablation is a promising option for recurrent localized cervical cancer in non-surgical candidates who fail platinum-based chemotherapy and radiation. We developed a low-cost polymer-assisted ethanol ablative therapy, Point-of-care Ethanol Ethyl Cellulose (PEEC), that overcomes the main shortcoming of ethanol ablation: off-target ethanol leakage. Since increased tumor coverage of ablative therapies results in reduced tumor progression and improved clinical outcomes, we hypothesized that PEEC with image-guidance would

optimize cervicovaginal tumor coverage resulting in decreased tumor progression and off-target effects.

Methods A syngeneic cervicovaginal tumor model was established in C57BL/6 mice using TC1-Luc, HPV16 E6/E7+ cells expressing luciferase. Mice were randomized into image-guided PEEC (IG-PEEC), PEEC without image guidance (PEEC only), and saline ablation groups (n=5). Tumors were monitored with bioluminescence imaging via a Perkin-Elmer in vivo imaging system (IVIS) and calipers. Ablations consisted of two intratumoral injections (50μL each) of either PEEC or saline. Image-guided ablations were performed using IVIS to both target PEEC injections at regions of highest radiance intensity (correlated to tumor mass) and to assess tumor coverage.

Results Tumors treated with IG-PEEC performed best with lower total radiance, volumes and weights, and longer survival compared to PEEC only and saline groups (p < 0.05); both PEEC groups demonstrated reduced tumor growth compared to saline (p < 0.05). off-target damage (ulceration) rates were lower for the IG-PEEC (n=0, 0%) versus the PEEC only (n=2, 40%) group.

Conclusions PEEC ablation enhanced by image-guidance significantly controls HPV16 E6/E7+ cervicovaginal tumor progression. This supports image-guidance as a critical component in optimizing PEEC ablation and eventual clinical translation.

EPV053/#282

OBSTETRICAL AND ONCOLOGIC OUTCOMES AFTER ABDOMINAL RADICAL TRACHELECTOMY

ME Capilna*. 'George Emil Palade' University of Medicine, Pharmacy, Science and Technology, First Obstetrics and Gynecology Clinic, Targu Mures, Romania

10.1136/ijgc-2021-IGCS.121

Objectives To describe retrospectively our experience following abdominal radical trachelectomy (ART), including 5 performed during pregnancy, in terms of complications, obstetrical and oncologic outcomes.

Methods Between 2010 and 2020, all patients with early stage cervical cancer deserving to preserve their fertility were considered for ART. Out of the 19 patients who have met the inclusion criteria for ART, in 18 the trachelectomy was performed and only 1 case needed conversion to radical hysterectomy.

Results Patients' mean age was 31 years old (range 24- 38); two thirds of them were nulliparous. Six women (33.33%) were staged as IA2, 4 (22.22%) IB1, 5 (27.78%) IB2, and 4 (22.22%) stage IB3 disease. Only one intraoperative complication has occurred - both bladder and right ureteral injuries. Early postoperative complications were urinary bladder dysfunction (33.33%), symptomatic pelvic lymphocele which was drained (11.1%), peritonitis (5.5%), and wound infection (5.5%). Late postoperative complications included cervical stenosis (5.5%), amenorrhea (11.1%), and pelvic abscess (5.5%). Four out of the 18 patients were operated during pregnancy between 14 and 20 weeks; 2 of them have delivered at term, and 2 of them have aborted shortly after the surgery. One patient was operated immediately after caesarean section. Two vaginal recurrences were recorded; and both have been managed by hysterectomy, partial colpectomy and adjuvant chemoradiotherapy. At this moment, all patients are alive with no evidence of disease and 3 of them managed to conceive.